EditorialHow gene discovery has transformed management of people with epilepsy
References (7)
- et al.
De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy
Am. J. Hum. Genet.
(2001) - et al.
ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology
Epilepsia
(2017) - et al.
Epilepsy and developmental disorders: next generation sequencing in the clinic
Eur. J. Paediatr. Neurol.
(2019)
There are more references available in the full text version of this article.
Cited by (1)
Genetic-cellular epilepsy: Clues to diagnosing newborns with neonatal seizures
2021, SeizureCitation Excerpt :Increasing knowledge that genetic testing results sometimes necessitate specific treatment implies the need for early diagnosis of GCE. Furthermore, targeted gene therapies have already been proved to have excellent efficacy in mouse models and will probably change the therapeutic approach in the future [27]. It has been established that SCN2A and KCNQ2-related early onset epileptic encephalopathies react well to sodium channel blockers such as phenytoin or carbamazepine [6,7].
© 2020 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.